ZNF263 and glioblastoma: Intriguingly, Trametinib appeared to specifically reduce ZNF263 protein levels without altering those of KAP1, SUV39H2, EED, or SETDB1, implying that the activation of EGFR/MAPK led to SIX3 silencing in glioblastoma mainly through the regulation of ZNF263 (Fig. S6C).